Cargando…

Impact of Reduced Renal Function on the Glucose-Lowering Effects of Luseogliflozin, a Selective SGLT2 Inhibitor, Assessed by Continuous Glucose Monitoring in Japanese Patients with Type 2 Diabetes Mellitus

INTRODUCTION: We investigated the impact of reduced renal function on 24-h glucose variability in Japanese patients with type 2 diabetes mellitus (T2DM) treated with luseogliflozin. METHODS: In this double-blind, placebo-controlled, crossover study, 37 Japanese patients with T2DM [glycated hemoglobi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Jinnouchi, Hideaki, Nozaki, Kazunari, Watase, Hirotaka, Omiya, Hirohisa, Sakai, Soichi, Samukawa, Yoshishige
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Healthcare 2016
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4833807/ https://www.ncbi.nlm.nih.gov/pubmed/26846284 http://dx.doi.org/10.1007/s12325-016-0291-z

Ejemplares similares

Substantial Effects of Luseogliflozin Revealed by Analyzing Responses to Postprandial Hyperglycemia: Post Hoc Subanalyses of a Randomized Controlled Study
por: Samukawa, Yoshishige, et al.
Publicado: (2016)

Pharmacokinetics and Pharmacodynamics of Luseogliflozin, a Selective SGLT2 Inhibitor, in Japanese Patients With Type 2 Diabetes With Mild to Severe Renal Impairment
por: Samukawa, Yoshishige, et al.
Publicado: (2018)

Effects of luseogliflozin, a sodium–glucose co‐transporter 2 inhibitor, on 24‐h glucose variability assessed by continuous glucose monitoring in Japanese patients with type 2 diabetes mellitus: a randomized, double‐blind, placebo‐controlled, crossover study
por: Nishimura, R., et al.
Publicado: (2015)

Absence of Drug–Drug Interactions Between Luseogliflozin, a Sodium–Glucose Co-transporter-2 Inhibitor, and Various Oral Antidiabetic Drugs in Healthy Japanese Males
por: Sasaki, Takashi, et al.
Publicado: (2015)

Sodium‐glucose cotransporter 2 inhibitor luseogliflozin improves glycaemic control, assessed by continuous glucose monitoring, even on a low‐carbohydrate diet
por: Nishimura, R., et al.
Publicado: (2016)

Pharmacokinetics, Pharmacodynamics, and Safety of Luseogliflozin in Japanese Patients with Type 2 Diabetes Mellitus: A Randomized, Single-blind, Placebo-controlled Trial
por: Sasaki, Takashi, et al.
Publicado: (2015)

Randomized, Controlled, Thorough QT/QTc Study Shows Absence of QT Prolongation with Luseogliflozin in Healthy Japanese Subjects
por: Kumagai, Yuji, et al.
Publicado: (2015)

Efficacy and safety of luseogliflozin added to various oral antidiabetic drugs in Japanese patients with type 2 diabetes mellitus
por: Seino, Yutaka, et al.
Publicado: (2015)

Safety, Pharmacokinetics, and Pharmacodynamics of Single and Multiple Luseogliflozin Dosing in Healthy Japanese Males: A Randomized, Single-Blind, Placebo-Controlled Trial
por: Sasaki, Takashi, et al.
Publicado: (2014)

Using a Mathematical Modeling To Simulate Pharmacokinetics and Urinary Glucose Excretion of Luseogliflozin and Explore the Role of SGLT1/2 in Renal Glucose Reabsorption
por: Wang, Zhongjian, et al.
Publicado: (2022)

Luseogliflozin, a SGLT2 Inhibitor, Does Not Affect Glucose Uptake Kinetics in Renal Proximal Tubules of Live Mice
por: Zhang, Anqi, et al.
Publicado: (2021)

Treatment with the SGLT2 inhibitor luseogliflozin improves nonalcoholic steatohepatitis in a rodent model with diabetes mellitus
por: Qiang, Shirong, et al.
Publicado: (2015)

SGLT2 inhibitor lowers serum uric acid through alteration of uric acid transport activity in renal tubule by increased glycosuria
por: Chino, Yukihiro, et al.
Publicado: (2014)

Reduction of Excessive Visceral Fat and Safety with 52-Week Administration of Lipase Inhibitor Orlistat in Japanese: Long-Term Clinical Study
por: Shirai, Kohji, et al.
Publicado: (2018)

Sodium‐glucose cotransporter‐2 inhibitor luseogliflozin added to glucagon‐like peptide 1 receptor agonist liraglutide improves glycemic control with bodyweight and fat mass reductions in Japanese patients with type 2 diabetes: A 52‐week, open‐label, single‐arm study
por: Seino, Yutaka, et al.
Publicado: (2017)

Effect of the sodium–glucose cotransporter 2 inhibitor luseogliflozin on pancreatic beta cell mass in db/db mice of different ages
por: Takahashi, Kiyohiko, et al.
Publicado: (2018)

Efficacy and Safety of Lipase Inhibitor Orlistat in Japanese with Excessive Visceral Fat Accumulation: 24-Week, Double-Blind, Randomized, Placebo-Controlled Study
por: Shirai, Kohji, et al.
Publicado: (2018)

Extracellular lipidome change by an SGLT2 inhibitor, luseogliflozin, contributes to prevent skeletal muscle atrophy in db/db mice
por: Bamba, Ryo, et al.
Publicado: (2021)

Physiology of renal glucose handling via SGLT1, SGLT2 and GLUT2
por: Ghezzi, Chiara, et al.
Publicado: (2018)

Luseogliflozin Additively Enhances the Glucose-Lowering Effect of an Incretin Modulator in a High-Carbohydrate Diet
por: Lee, Gendai
Publicado: (2022)

Factors Influencing Change in Serum Uric Acid After Administration of the Sodium‐Glucose Cotransporter 2 Inhibitor Luseogliflozin in Patients With Type 2 Diabetes Mellitus
por: Chino, Yukihiro, et al.
Publicado: (2021)

Influence of Luseogliflozin on Vaginal Bacterial and Fungal Populations in Japanese Patients With Type 2 Diabetes
por: Kusunoki, Masataka, et al.
Publicado: (2021)

Luseogliflozin inhibits high glucose-induced TGF-β2 expression in mouse cardiomyocytes by suppressing NHE-1 activity
por: Osaka, Naoya, et al.
Publicado: (2022)

Observational Study on Unhealthy Eating Behavior and the Effect of Sodium-Glucose Cotransporter 2 Inhibitors: The Luseogliflozin Ehime Diabetes Study
por: Furukawa, Shinya, et al.
Publicado: (2022)

Osmotic Water Transport with Glucose in GLUT2 and SGLT
por: Naftalin, Richard J.
Publicado: (2008)

SGLT2i: beyond the glucose-lowering effect
por: Ni, Lihua, et al.
Publicado: (2020)

Sodium glucose transporter 2 (SGLT2) inhibition and ketogenesis
por: Kalra, Sanjay, et al.
Publicado: (2015)

Mouse Models with SGLT2 Mutations: Toward Understanding the Role of SGLT2 beyond Glucose Reabsorption
por: Unno, Keiko, et al.
Publicado: (2023)

Hypoglycemia in blood glucose level in type 2 diabetic Japanese patients by continuous glucose monitoring
por: Hajime, Maiko, et al.
Publicado: (2019)

The sodium-glucose cotransporter 2 inhibitor luseogliflozin can suppress muscle atrophy in Db/Db mice by suppressing the expression of foxo1
por: Okamura, Takuro, et al.
Publicado: (2019)

Gut Microbiota Changes by an SGLT2 Inhibitor, Luseogliflozin, Alters Metabolites Compared with Those in a Low Carbohydrate Diet in db/db Mice
por: Hata, Shinnosuke, et al.
Publicado: (2022)

Targeting high glucose-induced epigenetic modifications at cardiac level: the role of SGLT2 and SGLT2 inhibitors
por: Scisciola, Lucia, et al.
Publicado: (2023)

Sodium–glucose cotransporter 2 inhibitor‐induced changes in body composition and simultaneous changes in metabolic profile: 52‐week prospective LIGHT (Luseogliflozin: the Components of Weight Loss in Japanese Patients with Type 2 Diabetes Mellitus) Study
por: Sasaki, Takashi, et al.
Publicado: (2018)

Excretion of glucose analogue with SGLT2 affinity predicts response effectiveness to sodium glucose transporter 2 inhibitors in patients with type 2 diabetes mellitus
por: Geist, Barbara Katharina, et al.
Publicado: (2023)

Efficacy and safety of dapagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, in diabetes mellitus
por: Fioretto, Paola, et al.
Publicado: (2015)

Review on sodium-glucose cotransporter 2 inhibitor (SGLT2i) in diabetes mellitus and heart failure
por: Pradhan, Akshyaya, et al.
Publicado: (2019)

Ghrelin Facilitates GLUT2-, SGLT1- and SGLT2-mediated Intestinal Glucose Transport in Goldfish (Carassius auratus)
por: Blanco, Ayelén Melisa, et al.
Publicado: (2017)

A Fluorescent Glucose Transport Assay for Screening SGLT2 Inhibitors in Endogenous SGLT2-Expressing HK-2 Cells
por: Lu, Yan-Ting, et al.
Publicado: (2018)

The effect of sodium/glucose cotransporter 2 (SGLT2) inhibition on the urinary proteome
por: Cherney, David, et al.
Publicado: (2017)

Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitors: A Clinician’s Guide
por: Simes, Bryce C, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_g0lis7vsv0man9b25fn6bf1h97